- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00612664
Phase II, 2nd Line Melanoma - RAND Monotherapy
September 23, 2015 updated by: Bristol-Myers Squibb
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Study Overview
Study Type
Interventional
Enrollment (Actual)
158
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Local Institution
-
Edmonton, Alberta, Canada, T6G 1Z2
- Local Institution
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
- Local Institution
-
-
-
-
-
Aarhus C, Denmark, 8000
- Local Institution
-
Odense C, Denmark, DK-5000
- Local Institution
-
-
-
-
-
Lille, France, 59037
- Local Institution
-
Paris, France, 75010
- Local Institution
-
Paris Cedex 13, France, 75651
- Local Institution
-
Vandoeuvre Les Nancy, France, 54511
- Local Institution
-
Villejuif, France, 94805
- Local Institution
-
-
-
-
-
Homburg / Saar, Germany, 66421
- Local Institution
-
Jena, Germany, 07740
- Local Institution
-
Kiel, Germany, 24105
- Local Institution
-
Mainz, Germany, 55131
- Local Institution
-
Mannheim, Germany, 68167
- Local Institution
-
Tubingen, Germany, 72076
- Local Institution
-
Wuerzburg, Germany, 97080
- Local Institution
-
-
-
-
-
Genove, Italy, 16132
- Local Institution
-
Milano, Italy, 20141
- Local Institution
-
Napoli, Italy, 80131
- Local Institution
-
Padova, Italy, 35128
- Local Institution
-
Siena, Italy, 53100
- Local Institution
-
-
-
-
California
-
Los Angeles, California, United States, 90025
- The Angeles Clinic & Research Institute
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University School of Medicine
-
-
Illinois
-
Park Ridge, Illinois, United States, 60068
- Oncology Specialists, S.C.
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21237
- Harry & Jeanette Weinberg Cancer Inst At Franklin Square
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Inst
-
-
New York
-
New York, New York, United States, 10021
- Mem Sloan-Ket Can Ctr
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Blumenthal Cancer Center, Carolinas Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvant and/or neoadjuvant therapy, the subject must have documented disease progression from the last treatment and also received one additional line of systemic therapy for metastatic disease.
- Men and women, who are at least 18 years of age
Exclusion Criteria:
- Ocular or mucosal melanoma
- Complete surgical resection of all identifiable sites of disease
- Symptomatic brain metastasis. Subjects with signs or symptoms suggestive of brain metastasis are not eligible unless brain metastases are ruled out by computerized axial tomography (CT) scan or magnetic resonance imaging (MRI). Subjects with stable brain metastasis and those who were previously treated with radiotherapy or surgery must have no current evidence of symptomatic brain metastasis and are off steroid therapy for at least 4 weeks prior to randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1
0.1 mg/kg every 3 weeks
|
IV solution, IV, until PD or toxicity
|
Active Comparator: Arm 2
1 mg/kg every 3 weeks
|
IV solution, IV, until PD or toxicity
|
Active Comparator: Arm 3
1 mg/kg every 6 weeks
|
IV solution, IV, until PD or toxicity
|
Active Comparator: Arm 4
5 mg/kg every 3 weeks
|
IV solution, IV, until PD or toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate
Time Frame: every 6 weeks starting at week 12 after randomization
|
every 6 weeks starting at week 12 after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety profiles
Time Frame: throughout the study
|
throughout the study
|
Disease response rate
Time Frame: end of study
|
end of study
|
Disease control rate
Time Frame: end of study
|
end of study
|
1-year survival
Time Frame: end of study
|
end of study
|
Pharmacokinetics
Time Frame: throughout the study
|
throughout the study
|
Pharmacodynamics
Time Frame: throughout the study
|
throughout the study
|
Biomarkers
Time Frame: throughout the study
|
throughout the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
January 30, 2008
First Submitted That Met QC Criteria
January 30, 2008
First Posted (Estimate)
February 12, 2008
Study Record Updates
Last Update Posted (Estimate)
October 12, 2015
Last Update Submitted That Met QC Criteria
September 23, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA186-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on Anti-CD137 (4-1BB) (BMS-663513)
-
Bristol-Myers SquibbTerminatedNon Small Cell Lung CancerUnited States
-
Agenus Inc.Active, not recruitingAdvanced CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Iovance Biotherapeutics, Inc.; Prometheus Inc.CompletedSkin Cancer | Melanoma (Skin)United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditionsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)RecruitingPancreatic CancerUnited States
-
Shanghai HyaMab Biotech Co.,Ltd.CompletedLocally Advanced/Metastatic Solid TumorsChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Refractory GlioblastomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)CompletedGlioblastoma | Gliosarcoma | Recurrent Brain NeoplasmUnited States
-
Shanghai Henlius BiotechNot yet recruiting
-
Shanghai HyaMab Biotech Co.,Ltd.RecruitingLocally Advanced/Metastatic Solid TumorsChina